Results 101 to 110 of about 31,038,441 (242)

Sphingosine 1-phosphate signalling in mammalian cells [PDF]

, 2000
Sphingosine 1-phosphate is formed in cells in response to diverse stimuli, including growth factors, cytokines, G-protein-coupled receptor agonists, antigen, etc. Its production is catalysed by sphingosine kinase, while degradation is either via cleavage
Nigel J. PYNE, Susan PYNE, Pyne, S, Pyne, N J   +3 more
core   +1 more source

Sphingosine-1-Phosphate Receptor 5 Modulates Early-Stage Processes during Fibrogenesis in a Mouse Model of Systemic Sclerosis: A Pilot Study

Frontiers in Immunology, 2017
Systemic sclerosis (SSc) is a rare multi-organ autoimmune disease characterized by progressive skin fibrosis. Inflammation, type 2 immunity, and fibrogenic processes are involved in disease development and may be affected by sphingolipids.
Katrin G. Schmidt, Martina Herrero San Juan, Sandra Trautmann, Lucija Berninger, Anja Schwiebs, Florian M. Ottenlinger, Dominique Thomas, Frank Zaucke, Josef M. Pfeilschifter, Heinfried H. Radeke   +9 more
doaj   +1 more source

Reproductive Challenges of the Ageing Female: A Comprehensive Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Changes in societal norms over the last few decades have resulted in novel family planning trends, notably delayed childbearing and increased maternal age at the birth of the first child. Despite advances in reproductive medicine, ageing poses significant challenges.
Sofia Bitzika, Meletios P. Nigdelis, Angelos Daniilidis, Erich‐Franz Solomayer, Irene Lambrinoudaki, Efstratios M. Kolibianakis, Dimitrios G. Goulis   +6 more
wiley   +1 more source

Emollient Formulations and Skin Barrier Practices in the Context of Eczema and Food Allergy Prevention

Allergy, EarlyView.
ABSTRACT The skin is far from a passive shield; it functions as a dynamic “living barrier” whose structural and immunological integrity is paramount in preventing atopic dermatitis (AD) and the subsequent progression of the atopic march toward food allergy (FA).
Klaudia Ryczaj, Donald Y. M. Leung, Carina Venter, Barbara Sozańska, Helen A. Brough   +4 more
wiley   +1 more source

Individual variation of human S1P1 coding sequence leads to heterogeneity in receptor function and drug interactions[S]

Journal of Lipid Research, 2014
Sphingosine 1-phosphate receptor 1 (S1P1), an abundantly-expressed G protein-coupled receptor which regulates key vascular and immune responses, is a therapeutic target in autoimmune diseases. Fingolimod/Gilenya (FTY720), an oral medication for relapsing-
Hideru Obinata, Sarah Gutkind, Jeremiah Stitham, Toshiaki Okuno, Takehiko Yokomizo, John Hwa, Timothy Hla   +6 more
doaj   +1 more source

The nitty‐gritty of vascular permeability in cancer: targeting blood endothelium to control metastases

British Journal of Pharmacology, EarlyView.
Blood vascular permeability is a hallmark of cancer and acts as an active driver of metastatic dissemination. Metastasis accounts for the vast majority of cancer deaths, yet most work has focussed on tumour‐intrinsic traits and angiogenesis, while the specific contribution of endothelial barrier regulation to intravasation and extravasation remains ...
Pierre Boucher, Mérone Da Costa Oliveira, Adrien Levesque, Alexandre Rutault, Patrick Savoyaud, Nicolas Bréchot, Stéphane Germain   +6 more
wiley   +1 more source

Natural product‐derived TRPM7 channel inhibitors in neurological injury: Mechanisms, pharmacological potential and translational challenges

British Journal of Pharmacology, EarlyView.
Disruption of intracellular ionic homeostasis is a convergent pathological feature across diverse neurological injuries and disorders, including ischaemic and haemorrhagic stroke, hypoxic–ischaemic brain injury, traumatic brain injury, epilepsy and brain tumour.
Xinyang Zhang, Hio Lam Ho, F. David Horgen, Andrea Fleig, Zhong‐Ping Feng, Hong‐Shuo Sun   +5 more
wiley   +1 more source

Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis

, 2017
Since the approval of fingolimod, several selective sphingosine-1-phosphate receptor modulators have entered clinical development for multiple sclerosis. However, side effects can occur with sphingosine-1-phosphate receptor modulators.
Heinz Wiendl, Hartung, Hans peter, Bakshi, Rajesh, Hans-Peter Hartung, Rajesh Bakshi, COMI, GIANCARLO, Williams, Ian M., Wiendl, Heinz, Ian M. Williams, Giancarlo Comi   +9 more
core   +1 more source

Deficiency of sphingosine-1-phosphate receptor 3 does not affect the skeletal phenotype of mice lacking sphingosine-1-phosphate lyase.

PLoS ONE, 2019
Albeit osteoporosis is one of the most prevalent disorders in the aged population, treatment options stimulating the activity of bone-forming osteoblasts are still limited.
Timo Heckt, Laura J Brylka, Mona Neven, Michael Amling, Thorsten Schinke   +4 more
doaj   +1 more source

Sphingosine‐1‐Phosphate Receptor 1 Regulates Cardiac Function by Modulating Ca2+ Sensitivity and Na+/H+ Exchange and Mediates Protection by Ischemic Preconditioning

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundSphingosine‐1‐phosphate plays vital roles in cardiomyocyte physiology, myocardial ischemia–reperfusion injury, and ischemic preconditioning. The function of the cardiomyocyte sphingosine‐1‐phosphate receptor 1 (S1P1) in vivo is unknown. Methods
Petra Keul, Marcel M. G. J. van Borren, Alexander Ghanem, Frank Ulrich Müller, Antonius Baartscheer, Arie O. Verkerk, Frank Stümpel, Jan Sebastian Schulte, Nazha Hamdani, Wolfgang A. Linke, Pieter van Loenen, Marek Matus, Wilhelm Schmitz, Jörg Stypmann, Klaus Tiemann, Jan‐Hindrik Ravesloot, Astrid E. Alewijnse, Sven Hermann, Léon J. A. Spijkers, Karl‐Heinz Hiller, Deron Herr, Gerd Heusch, Michael Schäfers, Stephan L. M. Peters, Jerold Chun, Bodo Levkau   +25 more
doaj   +1 more source